• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Denali Therapeutics Inc (NQ: DNLI )

    30.91 -0.14 (-0.45%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,997,843
    Open 30.94
    Bid (Size) 27.94 (1)
    Ask (Size) 30.90 (1)
    Prev. Close 31.05
    Today's Range 30.65 - 31.24
    52wk Range 14.56 - 32.13
    Shares Outstanding 121,640,069
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following
    From Denali Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    +44.51%
    +44.51%
    1 Month
    +23.64%
    +23.64%
    3 Month
    +36.59%
    +36.59%
    6 Month
    +57.54%
    +57.54%
    1 Year
    +37.44%
    +37.44%

    More News

    Read More
    4 Analysts Assess Denali Therapeutics: What You Need To Know
    Via Benzinga
    Denali Therapeutics: Q4 Earnings Insights
    Via Benzinga
    DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Stock Gets Technical Rating Upgrade
    Via Investor's Business Daily
    3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
    Via InvestorPlace
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    To the Moon and Beyond: 7 Stocks With Cosmic Potential
    Via InvestorPlace
    Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know
    Via Benzinga
    Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Announces $500 million Private Placement Equity Financing
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
    Via Benzinga
    3 Biotech Stocks to Buy for the Next Bull Run: February 2024
    Via InvestorPlace
    Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.